Navigation Links
VIA Pharmaceuticals to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
Date:5/8/2008

SAN FRANCISCO, May 8 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that James G. Stewart, senior vice president and chief financial officer, will present a company update at the Rodman & Renshaw 5th Annual Global Healthcare Conference on Monday, May 19, 2008 at 11:50 a.m. CEST at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
Interested parties may access a live audio webcast of the presentation from the investor section of the VIA website, http://www.viapharmaceuticals.com or at http://www.wsw.com/webcast/rrshq13/viap. A replay of the presentation will be archived on the VIA website for at least one week following the presentation. About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.


'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Memory Pharmaceuticals to Announce First Quarter 2008 Results on Wednesday, May 14, 2008
2. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
3. Amylin Pharmaceuticals to Present at Bank of America Healthcare Conference
4. Jazz Pharmaceuticals, Inc. to Announce First Quarter Results on May 13, 2008
5. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
6. Onyx Pharmaceuticals Reports 2008 First Quarter Results
7. SGX Pharmaceuticals Schedules Teleconference and Webcast to Discuss First Quarter 2008 Results and Provide Pipeline Update
8. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
9. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
10. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
11. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... Amendia, ... appointment of Steven F. McAllister as Executive Vice President and Chief Financial Officer. ... U.S. and international markets. Beginning his career at Howmedica, Inc., he has since ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... its Nor-Tech cluster with user-friendly bootable Intel KNL. , Currently Cal Tech ... into Nor-Tech’s demo cluster. The demo cluster is a no-cost, no-strings opportunity for ...
(Date:1/24/2017)... , ... January 23, 2017 , ... Oklahoma City based ... newest client for the firm’s PERFEQTA software and legacy product QC Manager 2.0. ... the dynamic team at CJBC and thrilled that they have decided to implement PERFEQTA ...
(Date:1/24/2017)... 23, 2017  Today, the Fisher Center for Alzheimer,s ... an important study that could lead to the development ... Alzheimer,s disease. This groundbreaking research was conducted by the ... Nobel Laureate Dr. Paul Greengard , in the ... Fisher Center scientists have linked a mutation that ...
Breaking Biology Technology:
(Date:1/18/2017)... -- In vitro diagnostic (IVD) companies were very active in ... Kalorama Information expects that trend to continue – though ... uncertainty in reimbursement and healthcare reform in ... acquisitions landscape. Instead of looking to buy technology, the ... of their home country and also to increase their ...
(Date:1/12/2017)... Jan. 12, 2017  New research undertaken by Fit ... the future.  1,000 participants were simply asked which office technology ... we may consider standard issue.  Insights on what will ... also gathered from futurists and industry leaders including Penelope ... Canton .  Some of these findings ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
Breaking Biology News(10 mins):